Coronavirus: tens of thousands of blood against the SARS are samples of anti-CoV-2 tested – Naturopathy naturopathy specialist portal

Study on Diabetes is now testing thousands of children for antibodies against SARS-CoV-2

In connection with a study for the early detection of type 1 Diabetes are already tens of thousands of blood samples were collected. These samples should now be tested for antibodies against SARS-CoV-2.

As the Helmholtz Zentrum München – German research center for environmental health, in a recent communication, writes, could help surface antibody tests against the new Coronavirus, SARS-CoV-2 to obtain realistic values of the Infection rate of the pathogen. Researchers refer to the end of a study, the children in Bavaria to test at an early stage of type 1 Diabetes, these Tests directly in your investigations.

Blood samples of children for type-1-Diabetes-early detection

More and more children develop type 1 Diabetes. The “Fr1da plus”-study: “type 1 Diabetes: Early detection – good treatment in Early stages” examines the less drop of blood whether a child is at an early stage of type 1 Diabetes is present.

These blood samples are now in the fight against the new Coronavirus to be used.

Together with an existing network of hundreds of child and youth doctors and physicians and under the direction of the Helmholtz Zentrum München, you could test up to 65,000 blood samples from the Fr1da-plus-study now also on the presence of antibodies against SARS-CoV-2.

Cooperation with more than 600 physician practices

As stated in the notification, collects “Fr1da plus” blood samples from children in Bavaria, at the age of 2-5 and 9-10 years of age for type 1 Diabetes-early detection.

These samples are now to be retroactively tested from August 2019 to today (about 15,000 samples) and continuing over the next two years (in the best case, around 50,000 samples depending on the financial resources) to antibodies against SARS – CoV-2.

The already existing sample collection and the close cooperation with more than 600 physician practices allows the Fr1da-plus researchers, the Tests immediately and on a large scale.

Still no proof of the immunity due to the presence of antibodies
The information suggests that the Tests are performed under the assumption that the presence of antibodies against the immune-dominant epitope of the SARS-CoV-2 Proteins, namely the receptor binding domain of S-Protein, is a statement about the individual’s immunity to allow.

Proof of immunity to SARS-CoV-2 due to the presence of specific antibodies, there is not currently. As soon as this is available, could be provided with the Tests and the relevant information to the immunity situation of children in Bavaria.

Important epidemiological findings expected

In addition to the frequency of SARS-CoV-2 infections in children in Bavaria, the Tests could also provide insights into the diffusion pattern, as well as any differences in Region, age and gender to capture.

As it says on the website to study, could provide a comprehensive antibody testing against SARS-CoV-2, with realistic values about the increasing herd immunity.

Particularly interesting for the scientists of Fr1da plus is also whether there is a relationship between the presence and the number of anti-bodies, which consists in pre-symptomatic type 1 Diabetes, and antibodies against SARS-CoV-2 – that is to say, whether the risk of the children to the autoimmune disease type 1 develop Diabetes with an increased risk of a COVID-19-disease hand-in-hand could go.

Prof. Anette-Gabriele Ziegler, Director of the Fr1da plus study and Director of the Institute for diabetes research at Helmholtz Zentrum München, said:

“Our existing large network of pediatric practices in Bavaria offers best conditions, the epidemiological research on exposure frequency to COVID-19 to advance and to make an important contribution to the Corona research. We expect to be able to first test results in the fall of 2020 to deliver.“

Tests are not suitable for early diagnostics

The research project is conducted in cooperation with the science Vito Lampasona and Dr. Lorenzo Piemonti at the San Rafael hospital in Milan (Italy) learning, developed by the non-commercial anti-body test.

According to the figures, the Test is a Luciferase immuno-precipitation Test (LIPS Assay) against SARS-CoV-2, which works according to a principle similar to the already existing insulin anti-body Test of the Fr1da-plus study.

The Helmholtz Zentrum München also points to the limitations of the study: The described antibody tests for SARS-CoV-2 only with participation at Fr1da plus possible. They are not suitable for early diagnosis of an acute infection because antibodies occur in the course of a disease only slowly. (ad)